Which has stronger valuation & earnings, BMRN or GRAL?

BioMarin Pharmaceutical has higher revenue and earnings than GRAIL. GRAIL is trading at a lower price-to-earnings ratio than BioMarin Pharmaceutical, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio BioMarin Pharmaceutical $3.22B 4.01 $348.90M $0.37 180.27 GRAIL $147.17M 24.14 -$408.35M -$9.75 N/A

Does the media refer more to BMRN or GRAL?

In the previous week, BioMarin Pharmaceutical had 32 more articles in the media than GRAIL. MarketBeat recorded 34 mentions for BioMarin Pharmaceutical and 2 mentions for GRAIL. GRAIL's average media sentiment score of 1.22 beat BioMarin Pharmaceutical's score of 0.73 indicating that GRAIL is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment BioMarin Pharmaceutical 13 Very Positive mention(s) 5 Positive mention(s) 9 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Positive GRAIL 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer ARWR or GRAL?

In the previous week, Arrowhead Pharmaceuticals had 13 more articles in the media than GRAIL. MarketBeat recorded 15 mentions for Arrowhead Pharmaceuticals and 2 mentions for GRAIL. GRAIL's average media sentiment score of 1.22 beat Arrowhead Pharmaceuticals' score of 0.90 indicating that GRAIL is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Arrowhead Pharmaceuticals 10 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive GRAIL 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has higher valuation & earnings, HALO or GRAL?

Halozyme Therapeutics has higher revenue and earnings than GRAIL. GRAIL is trading at a lower price-to-earnings ratio than Halozyme Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Halozyme Therapeutics $1.66B 7.38 $316.89M $3.35 32.29 GRAIL $147.17M 24.14 -$408.35M -$9.75 N/A

Does the media prefer HALO or GRAL?

In the previous week, Halozyme Therapeutics had 13 more articles in the media than GRAIL. MarketBeat recorded 15 mentions for Halozyme Therapeutics and 2 mentions for GRAIL. GRAIL's average media sentiment score of 1.22 beat Halozyme Therapeutics' score of 1.04 indicating that GRAIL is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Halozyme Therapeutics 10 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive GRAIL 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has better valuation & earnings, MDGL or GRAL?

Madrigal Pharmaceuticals has higher revenue and earnings than GRAIL. Madrigal Pharmaceuticals is trading at a lower price-to-earnings ratio than GRAIL, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Madrigal Pharmaceuticals $958.40M 12.45 -$288.28M -$12.89 N/A GRAIL $147.17M 24.14 -$408.35M -$9.75 N/A

Does the media refer more to MDGL or GRAL?

In the previous week, Madrigal Pharmaceuticals had 5 more articles in the media than GRAIL. MarketBeat recorded 7 mentions for Madrigal Pharmaceuticals and 2 mentions for GRAIL. GRAIL's average media sentiment score of 1.22 beat Madrigal Pharmaceuticals' score of 1.08 indicating that GRAIL is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Madrigal Pharmaceuticals 5 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive GRAIL 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has better earnings & valuation, ABVX or GRAL?

Abivax has higher earnings, but lower revenue than GRAIL. Abivax is trading at a lower price-to-earnings ratio than GRAIL, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Abivax N/A N/A -$380.27M -$5.21 N/A GRAIL $147.17M 24.14 -$408.35M -$9.75 N/A

Is ABVX or GRAL more profitable?

Abivax has a net margin of 0.00% compared to GRAIL's net margin of -236.95%. GRAIL's return on equity of -15.88% beat Abivax's return on equity. Company Net Margins Return on Equity Return on Assets Abivax N/A -99.02% -70.26% GRAIL -236.95% -15.88% -14.02%

Does the media refer more to ABVX or GRAL?

In the previous week, GRAIL had 1 more articles in the media than Abivax. MarketBeat recorded 2 mentions for GRAIL and 1 mentions for Abivax. Abivax's average media sentiment score of 1.76 beat GRAIL's score of 1.22 indicating that Abivax is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Abivax 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive GRAIL 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

GRAIL (GRAL) Competitors

$79.54 +1.57 (+2.01%)

As of 08/21/2026 04:00 PM Eastern

Compare

GRAL vs. BMRN, ARWR, HALO, MDGL, and ABVX

Should you buy GRAIL stock or one of its competitors? GRAIL's main competitors and comparable companies include BioMarin Pharmaceutical (BMRN), Arrowhead Pharmaceuticals (ARWR), Halozyme Therapeutics (HALO), Madrigal Pharmaceuticals (MDGL), and Abivax (ABVX). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does GRAIL compare to BioMarin Pharmaceutical?

BioMarin Pharmaceutical (NASDAQ:BMRN) and GRAIL (NASDAQ:GRAL) are both healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their valuation, earnings, risk, dividends, media sentiment, institutional ownership, analyst recommendations and profitability.

BioMarin Pharmaceutical has higher revenue and earnings than GRAIL. GRAIL is trading at a lower price-to-earnings ratio than BioMarin Pharmaceutical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BioMarin Pharmaceutical	$3.22B	4.01	$348.90M	$0.37	180.27
GRAIL	$147.17M	24.14	-$408.35M	-$9.75	N/A

BioMarin Pharmaceutical has a net margin of 2.14% compared to GRAIL's net margin of -236.95%. BioMarin Pharmaceutical's return on equity of 5.32% beat GRAIL's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BioMarin Pharmaceutical	2.14%	5.32%	3.69%
GRAIL	-236.95%	-15.88%	-14.02%

In the previous week, BioMarin Pharmaceutical had 32 more articles in the media than GRAIL. MarketBeat recorded 34 mentions for BioMarin Pharmaceutical and 2 mentions for GRAIL. GRAIL's average media sentiment score of 1.22 beat BioMarin Pharmaceutical's score of 0.73 indicating that GRAIL is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
BioMarin Pharmaceutical	13 Very Positive mention(s)	5 Positive mention(s)	9 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Positive
GRAIL	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

BioMarin Pharmaceutical has a beta of 0.24, meaning that its stock price is 76% less volatile than the broader market. Comparatively, GRAIL has a beta of 3.24, meaning that its stock price is 224% more volatile than the broader market.

BioMarin Pharmaceutical presently has a consensus price target of $88.83, suggesting a potential upside of 33.17%. GRAIL has a consensus price target of $67.78, suggesting a potential downside of 14.79%. Given BioMarin Pharmaceutical's stronger consensus rating and higher possible upside, research analysts plainly believe BioMarin Pharmaceutical is more favorable than GRAIL.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BioMarin Pharmaceutical	1 Sell rating(s)	6 Hold rating(s)	15 Buy rating(s)	2 Strong Buy rating(s)	2.75
GRAIL	1 Sell rating(s)	5 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.30

98.7% of BioMarin Pharmaceutical shares are held by institutional investors. 0.7% of BioMarin Pharmaceutical shares are held by insiders. Comparatively, 1.8% of GRAIL shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Summary

BioMarin Pharmaceutical beats GRAIL on 13 of the 17 factors compared between the two stocks.

How does GRAIL compare to Arrowhead Pharmaceuticals?

Arrowhead Pharmaceuticals (NASDAQ:ARWR) and GRAIL (NASDAQ:GRAL) are both healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their dividends, risk, valuation, earnings, institutional ownership, analyst recommendations, profitability and media sentiment.

Arrowhead Pharmaceuticals has higher revenue and earnings than GRAIL. Arrowhead Pharmaceuticals is trading at a lower price-to-earnings ratio than GRAIL, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Arrowhead Pharmaceuticals	$829.45M	14.79	-$1.63M	-$2.25	N/A
GRAIL	$147.17M	24.14	-$408.35M	-$9.75	N/A

62.6% of Arrowhead Pharmaceuticals shares are held by institutional investors. 3.6% of Arrowhead Pharmaceuticals shares are held by company insiders. Comparatively, 1.8% of GRAIL shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Arrowhead Pharmaceuticals has a beta of 1.27, meaning that its stock price is 27% more volatile than the broader market. Comparatively, GRAIL has a beta of 3.24, meaning that its stock price is 224% more volatile than the broader market.

In the previous week, Arrowhead Pharmaceuticals had 13 more articles in the media than GRAIL. MarketBeat recorded 15 mentions for Arrowhead Pharmaceuticals and 2 mentions for GRAIL. GRAIL's average media sentiment score of 1.22 beat Arrowhead Pharmaceuticals' score of 0.90 indicating that GRAIL is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Arrowhead Pharmaceuticals	10 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
GRAIL	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Arrowhead Pharmaceuticals currently has a consensus target price of $97.33, suggesting a potential upside of 11.74%. GRAIL has a consensus target price of $67.78, suggesting a potential downside of 14.79%. Given Arrowhead Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe Arrowhead Pharmaceuticals is more favorable than GRAIL.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Arrowhead Pharmaceuticals	1 Sell rating(s)	3 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.62
GRAIL	1 Sell rating(s)	5 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.30

Arrowhead Pharmaceuticals has a net margin of -47.79% compared to GRAIL's net margin of -236.95%. GRAIL's return on equity of -15.88% beat Arrowhead Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Arrowhead Pharmaceuticals	-47.79%	-60.06%	-17.37%
GRAIL	-236.95%	-15.88%	-14.02%

Summary

Arrowhead Pharmaceuticals beats GRAIL on 10 of the 16 factors compared between the two stocks.

How does GRAIL compare to Halozyme Therapeutics?

Halozyme Therapeutics (NASDAQ:HALO) and GRAIL (NASDAQ:GRAL) are both healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, risk, analyst recommendations, earnings, valuation, profitability, media sentiment and dividends.

In the previous week, Halozyme Therapeutics had 13 more articles in the media than GRAIL. MarketBeat recorded 15 mentions for Halozyme Therapeutics and 2 mentions for GRAIL. GRAIL's average media sentiment score of 1.22 beat Halozyme Therapeutics' score of 1.04 indicating that GRAIL is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Halozyme Therapeutics	10 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
GRAIL	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Halozyme Therapeutics has a net margin of 24.86% compared to GRAIL's net margin of -236.95%. Halozyme Therapeutics' return on equity of 260.98% beat GRAIL's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Halozyme Therapeutics	24.86%	260.98%	23.91%
GRAIL	-236.95%	-15.88%	-14.02%

97.8% of Halozyme Therapeutics shares are owned by institutional investors. 2.5% of Halozyme Therapeutics shares are owned by insiders. Comparatively, 1.8% of GRAIL shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Halozyme Therapeutics has a beta of 0.85, meaning that its stock price is 15% less volatile than the broader market. Comparatively, GRAIL has a beta of 3.24, meaning that its stock price is 224% more volatile than the broader market.

Halozyme Therapeutics presently has a consensus price target of $91.20, indicating a potential downside of 15.69%. GRAIL has a consensus price target of $67.78, indicating a potential downside of 14.79%. Given GRAIL's higher possible upside, analysts plainly believe GRAIL is more favorable than Halozyme Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Halozyme Therapeutics	1 Sell rating(s)	3 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.62
GRAIL	1 Sell rating(s)	5 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.30

Halozyme Therapeutics has higher revenue and earnings than GRAIL. GRAIL is trading at a lower price-to-earnings ratio than Halozyme Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Halozyme Therapeutics	$1.66B	7.38	$316.89M	$3.35	32.29
GRAIL	$147.17M	24.14	-$408.35M	-$9.75	N/A

Summary

Halozyme Therapeutics beats GRAIL on 12 of the 16 factors compared between the two stocks.

How does GRAIL compare to Madrigal Pharmaceuticals?

Madrigal Pharmaceuticals (NASDAQ:MDGL) and GRAIL (NASDAQ:GRAL) are both healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their dividends, media sentiment, risk, institutional ownership, earnings, profitability, valuation and analyst recommendations.

Madrigal Pharmaceuticals has a beta of -1.01, suggesting that its stock price is 201% less volatile than the broader market. Comparatively, GRAIL has a beta of 3.24, suggesting that its stock price is 224% more volatile than the broader market.

98.5% of Madrigal Pharmaceuticals shares are held by institutional investors. 17.6% of Madrigal Pharmaceuticals shares are held by insiders. Comparatively, 1.8% of GRAIL shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Madrigal Pharmaceuticals has higher revenue and earnings than GRAIL. Madrigal Pharmaceuticals is trading at a lower price-to-earnings ratio than GRAIL, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Madrigal Pharmaceuticals	$958.40M	12.45	-$288.28M	-$12.89	N/A
GRAIL	$147.17M	24.14	-$408.35M	-$9.75	N/A

In the previous week, Madrigal Pharmaceuticals had 5 more articles in the media than GRAIL. MarketBeat recorded 7 mentions for Madrigal Pharmaceuticals and 2 mentions for GRAIL. GRAIL's average media sentiment score of 1.22 beat Madrigal Pharmaceuticals' score of 1.08 indicating that GRAIL is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Madrigal Pharmaceuticals	5 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
GRAIL	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Madrigal Pharmaceuticals currently has a consensus target price of $689.93, indicating a potential upside of 33.52%. GRAIL has a consensus target price of $67.78, indicating a potential downside of 14.79%. Given Madrigal Pharmaceuticals' stronger consensus rating and higher possible upside, equities research analysts plainly believe Madrigal Pharmaceuticals is more favorable than GRAIL.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Madrigal Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	15 Buy rating(s)	0 Strong Buy rating(s)	2.78
GRAIL	1 Sell rating(s)	5 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.30

Madrigal Pharmaceuticals has a net margin of -25.32% compared to GRAIL's net margin of -236.95%. GRAIL's return on equity of -15.88% beat Madrigal Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Madrigal Pharmaceuticals	-25.32%	-56.65%	-25.53%
GRAIL	-236.95%	-15.88%	-14.02%

Summary

Madrigal Pharmaceuticals beats GRAIL on 9 of the 16 factors compared between the two stocks.

How does GRAIL compare to Abivax?

Abivax (NASDAQ:ABVX) and GRAIL (NASDAQ:GRAL) are both healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their dividends, profitability, media sentiment, institutional ownership, risk, analyst recommendations, earnings and valuation.

In the previous week, GRAIL had 1 more articles in the media than Abivax. MarketBeat recorded 2 mentions for GRAIL and 1 mentions for Abivax. Abivax's average media sentiment score of 1.76 beat GRAIL's score of 1.22 indicating that Abivax is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Abivax	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
GRAIL	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Abivax has a net margin of 0.00% compared to GRAIL's net margin of -236.95%. GRAIL's return on equity of -15.88% beat Abivax's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Abivax	N/A	-99.02%	-70.26%
GRAIL	-236.95%	-15.88%	-14.02%

Abivax presently has a consensus price target of $156.50, indicating a potential upside of 36.15%. GRAIL has a consensus price target of $67.78, indicating a potential downside of 14.79%. Given Abivax's stronger consensus rating and higher possible upside, equities research analysts plainly believe Abivax is more favorable than GRAIL.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Abivax	1 Sell rating(s)	1 Hold rating(s)	13 Buy rating(s)	0 Strong Buy rating(s)	2.80
GRAIL	1 Sell rating(s)	5 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.30

Abivax has higher earnings, but lower revenue than GRAIL. Abivax is trading at a lower price-to-earnings ratio than GRAIL, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Abivax	N/A	N/A	-$380.27M	-$5.21	N/A
GRAIL	$147.17M	24.14	-$408.35M	-$9.75	N/A

Abivax has a beta of 1.03, meaning that its share price is 3% more volatile than the broader market. Comparatively, GRAIL has a beta of 3.24, meaning that its share price is 224% more volatile than the broader market.

47.9% of Abivax shares are held by institutional investors. 1.8% of GRAIL shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Summary

Abivax beats GRAIL on 8 of the 15 factors compared between the two stocks.

Get GRAIL News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding GRAL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

GRAL vs. The Competition

Export

Metric	GRAIL	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$3.55B	$4.01B	$7.37B	$12.85B
Dividend Yield	N/A	3.64%	2.53%	11.08%
P/E Ratio	-8.16	11.62	272.60	24.25
Price / Sales	24.14	1,338.15	618.96	99.05
Price / Cash	N/A	105.14	78.62	53.99
Price / Book	1.40	16.80	13.05	6.20
Net Income	-$408.35M	-$12.50M	$3.47B	$348.59M
7 Day Performance	17.19%	3.29%	2.09%	0.08%
1 Month Performance	13.05%	8.23%	6.64%	3.88%
1 Year Performance	132.30%	55.05%	25.02%	16.98%

GRAIL Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
GRAL GRAIL	1.1309 of 5 stars	$79.54 +2.0%	$67.78 -14.8%	+132.3%	$3.55B	$147.17M	N/A	1,360	Positive News
BMRN BioMarin Pharmaceutical	4.8151 of 5 stars	$68.88 +7.9%	$88.00 +27.8%	+13.9%	$12.35B	$3.22B	186.16	3,221	Analyst Forecast High Trading Volume
ARWR Arrowhead Pharmaceuticals	2.2395 of 5 stars	$88.33 +0.8%	$97.33 +10.2%	+308.4%	$12.35B	$829.45M	N/A	400	News Coverage Insider Trade
HALO Halozyme Therapeutics	3.8909 of 5 stars	$102.62 -0.5%	$91.20 -11.1%	+50.6%	$12.23B	$1.66B	30.63	390	Positive News Insider Trade High Trading Volume
MDGL Madrigal Pharmaceuticals	3.8051 of 5 stars	$515.34 +1.0%	$689.93 +33.9%	+24.6%	$11.78B	$958.40M	N/A	90	Positive News Insider Trade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:GRAL) was last updated on 8/23/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

GRAIL (GRAL) Competitors

GRAL vs. BMRN, ARWR, HALO, MDGL, and ABVX

How does GRAIL compare to BioMarin Pharmaceutical?

Summary

How does GRAIL compare to Arrowhead Pharmaceuticals?

Summary

How does GRAIL compare to Halozyme Therapeutics?

Summary

How does GRAIL compare to Madrigal Pharmaceuticals?

Summary

How does GRAIL compare to Abivax?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

GRAL vs. The Competition

GRAIL Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

GRAIL (GRAL) Competitors

GRAL vs. BMRN, ARWR, HALO, MDGL, and ABVX

How does GRAIL compare to BioMarin Pharmaceutical?

Which has stronger valuation & earnings, BMRN or GRAL?

Is BMRN or GRAL more profitable?

Does the media refer more to BMRN or GRAL?

Which has more risk and volatility, BMRN or GRAL?

Do analysts recommend BMRN or GRAL?

Do institutionals & insiders hold more shares of BMRN or GRAL?

Summary

How does GRAIL compare to Arrowhead Pharmaceuticals?

Which has better earnings and valuation, ARWR or GRAL?

Do insiders & institutionals hold more shares of ARWR or GRAL?

Which has more volatility and risk, ARWR or GRAL?

Does the media prefer ARWR or GRAL?

Do analysts recommend ARWR or GRAL?

Is ARWR or GRAL more profitable?

Summary

How does GRAIL compare to Halozyme Therapeutics?

Does the media prefer HALO or GRAL?

Is HALO or GRAL more profitable?

Do institutionals and insiders have more ownership in HALO or GRAL?

Which has more risk & volatility, HALO or GRAL?

Do analysts recommend HALO or GRAL?

Which has higher valuation & earnings, HALO or GRAL?

Summary

How does GRAIL compare to Madrigal Pharmaceuticals?

Which has more risk and volatility, MDGL or GRAL?

Do insiders & institutionals believe in MDGL or GRAL?

Which has better valuation & earnings, MDGL or GRAL?

Does the media refer more to MDGL or GRAL?

Do analysts prefer MDGL or GRAL?

Is MDGL or GRAL more profitable?

Summary

How does GRAIL compare to Abivax?

Does the media refer more to ABVX or GRAL?

Is ABVX or GRAL more profitable?

Do analysts recommend ABVX or GRAL?

Which has better earnings & valuation, ABVX or GRAL?

Which has more volatility & risk, ABVX or GRAL?

Do institutionals and insiders believe in ABVX or GRAL?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

GRAL vs. The Competition

GRAIL Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools